President Donald Trump disclosed stock purchases worth as much as $680,000 in Eli Lilly & Co. (NYSE:LLY) earlier this year, with the trades occurring as federal agencies under his administration advanced policies that benefited the drugmaker's obesity drug business.

Trump's Eli Lilly Purchases Coincided With GLP-1 Policy Developments

Citing disclosure forms signed by Trump, KFF Health News reported seven purchases of Eli Lilly shares through the end of March. The first transaction occurred on January 6, according to the filings.

The company, valued at nearly $1 trillion by the market, has become a major player in the growing GLP-1 weight-loss drug market.

The timing of the investments aligned with several administration initiatives tied to Medicare coverage of obesity treatments.

Among the most notable developments was a proposal from the Centers for Medicare & Medicaid Services for a pilot program that would allow Medicare patients to access GLP-1 drugs for